Entera Bio director buys 5,000 shares at $1.49

Entera Bio Ltd. director Steven D. Rubin reported an open-market purchase of 5,000 ordinary shares at $1.49 per share on February 12, 2026.

Rhea-AI Filing Summary

Entera Bio Ltd. director Steven D. Rubin reported an open-market purchase of 5,000 ordinary shares at $1.49 per share on February 12, 2026. Following this transaction, he directly beneficially owns 15,000 ordinary shares of Entera Bio.

Insider Trade Summary

Net Buyer: 5,000 shares

Net Buy 1 txn

Insider Rubin Steven D

Role Director

Bought 5,000 shs ($7K)

Type	Security	Shares	Price	Value
Purchase	Ordinary Shares, par value NIS 0.0000769 per share	5,000	$1.49	$7K

Holdings After Transaction: Ordinary Shares, par value NIS 0.0000769 per share — 15,000 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Entera Bio (ENTX) disclose in this Form 4?

Entera Bio reported that director Steven D. Rubin bought 5,000 ordinary shares in an open-market transaction. The shares were purchased on February 12, 2026, at a price of $1.49 per share, increasing his directly held stake to 15,000 shares.

Who is the insider involved in the latest Entera Bio (ENTX) Form 4 filing?

The insider is Steven D. Rubin, a director of Entera Bio Ltd. He reported an open-market purchase of ordinary shares, adding 5,000 shares on February 12, 2026, at $1.49 each, bringing his directly beneficially owned holding to 15,000 shares.

How many Entera Bio (ENTX) shares did the director buy and at what price?

Director Steven D. Rubin purchased 5,000 ordinary shares of Entera Bio at $1.49 per share. The transaction took place on February 12, 2026, and was reported as an open-market purchase, raising his directly owned position to 15,000 shares.

What is Steven D. Rubin’s Entera Bio (ENTX) share ownership after the reported trade?

After the reported transaction, director Steven D. Rubin beneficially owns 15,000 ordinary shares of Entera Bio directly. This follows his open-market purchase of 5,000 shares at $1.49 per share on February 12, 2026, as disclosed in the Form 4.

Was the Entera Bio (ENTX) insider trade a purchase or a sale?

The insider trade was a purchase. Director Steven D. Rubin executed an open-market buy of 5,000 ordinary shares on February 12, 2026, at a price of $1.49 per share, increasing his directly held beneficial ownership to 15,000 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 08:30 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rubin Steven D

(Last) (First) (Middle)

KIRYAT HADASSAH,

MINRAV BUILDING, 5TH FLOOR

(Street)

JERUSALEM L3 9112002

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Entera Bio Ltd. [ [ENTX] ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares, par value NIS 0.0000769 per share	02/12/2026		P		5,000	A	$1.49	15,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Dana Yaacov-Garbeli, Attorney-in-fact	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.